PCN30 A Real-World Analysis Of Korean Nation-Wide Database: Pattern, Adherence, And Associated Heatlhcare Costs Of Imatinib Among Patients With Chronic Myeloid Leukemia  by Shin, S et al.
A434  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
claims data to evaluate the relationship between dose modifications and persis-
tence among patients that receive 5 or more administrations. Methods: Using 
data from the Cardinal Health Specialty Solutions Revenue Cycle Management 
medical claims database, 267 patients who received 5 or more eribulin adminis-
trations and completed therapy between May 2014 and April 2015 were included 
in the analyses. The Relative Dose Intensity (RDI) methodology compared the 
intensity of dose received per day of treatment against expected dose (recom-
mended dose) intensity. RDI values and total number of eribulin administrations 
were calculated for each patient based on the presence or absence of either dose 
reduction and/or dose delay. Data was analyzed using an independent samples 
t-test. Results: An analysis of patient distribution revealed the mean number of 
eribulin administrations was 13.4 with a mean RDI of 85%. Persistence was statisti-
cally higher in patients that had eribulin therapy managed through dose delay and 
dose reduction strategies. Patients with no modification (100% RDI) received an 
average of 8.1 eribulin administrations. Patients with dose modification (81% RDI) 
received an average of 14.5 eribulin administrations (p < 0.001). ConClusions: 
Management of eribulin therapy in patients with MBC via dose delay and/or reduc-
tion resulted in a statistically significant increase in persistence among responding 
patients.
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A SyStemAtiC LiterAture review to ideNtify ANd ComPAre CLiNiCAL 
triALS evALuAtiNg NoveL therAPeutiC AgeNtS iN PoSt-gemCitAbiNe 
AdvANCed PANCreAtiC CANCer
Gaddy DF1, Becker C1, Li H1, Bennett R1, Yang Y2, Fitzgerald JB1, Bayever E1
1Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA, 2Baxalta, Inc., Cambridge, MA, USA
objeCtives: There is currently no standard of care for patients with advanced 
pancreatic cancer (APC), including locally advanced and metastatic disease, 
who progressed following first-line therapy. Available treatment options have 
been limited by a lack of therapeutic breakthroughs, and primarily utilize dif-
ferent combinations and dosing schedules of established chemotherapeutic 
agents. The current review assesses the relative efficacy of new therapeutic 
agents tested, alone or in combination, since 2003 in patients with APC who 
progressed following gemcitabine-based therapy. Methods: A systematic 
literature review was performed in PubMed/MEDLINE, EMBASE and ASCO 
meeting abstracts between January 2003 and June 2015. This review identi-
fied randomized controlled trials (RCTs) and single-arm trials evaluating new 
post-gemcitabine regimens in patients with APC. Results: A total of 34 trials, 
evaluating 1263 patients, were identified. New agents that have been tested 
include small molecules (24 trials), antibodies (3 trials), nanotherapeutics 
(4 trials), and immunotherapies (3 trials). The majority of studies were small, 
single-arm trials (n= 27). RCTs (n= 7, enrolling 835 patients) were further investi-
gated as they represent the standard for demonstrating therapeutic efficacy. At 
the time of analysis, the only Phase 3 RCT to evaluate a new therapeutic agent 
in post-gemcitabine APC was the NAPOLI-1 trial (nanoliposomal irinotecan 
(MM-398, nal-IRI) + 5-fluorouracil and leucovorin (5FU/LV) versus 5FU/LV), which 
was a large, global study that demonstrated a statistically significant improve-
ment in overall survival in patients with metastatic disease, including heavily-
pretreated patients. ConClusions: The present review highlights the limited 
number of RCTs evaluating new therapeutic agents in patients with APC who 
previously received gemcitabine. Most new agents fail to be evaluated beyond 
small, uncontrolled trials of APC. Despite much research in this difficult-to-treat 
patient population with high unmet medical need, only one Phase 3 RCT of a 
new agent (nal-IRI) + 5FU/LV demonstrated significant improvement in overall 
survival in patients with APC who had progressed following gemcitabine-based 
therapy.
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A reAL-worLd ANALySiS of KoreAN NAtioN-wide dAtAbASe: PAtterN, 
AdhereNCe, ANd ASSoCiAted heAtLhCAre CoStS of imAtiNib AmoNg 
PAtieNtS with ChroNiC myeLoid LeuKemiA
Shin S1, Lee J2, Kim J1, Shin M1, Kwon H1
1National Evidence based Health-care Collaborating Agency, Seoul, South Korea, 2National 
Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
objeCtives: This study aimed to determine the demographic features, treat-
ment pattern, medication adherence, survival rates and associated healthcare 
costs in patients with newly diagnosed Ph+ CML from Korean National health 
Insurance (NHI) claims database Methods: We conducted a longitudinal analy-
sis of patients with newly diagnosed Ph+ CML (ICD-10: C92.1) and started treat-
ment with imatinib in 2005 enrolled in the Korean NHI program. Patients were 
excluded if they had ≥ 1 claim with a diagnosis of other cancer within one year 
before diagnosis of CML. All data were retrieved from the NHI Database provided 
by National Health Insurance Corporation in Korea Results: In the study, a 
total of 8,986 patients with a diagnosis of Ph+ CML between January 1, 2004 and 
December 31, 2013 were identified. Among them, our study population consisted 
268 patients (mean age: 46.4±14.7 years, male: 57.4%) with the diagnosis of CML 
in 2005. The majority of patients (75.9%) initiated imatinib therapy at a starting 
dose was 400mg/day. With over 7 years of follow-up data, based on the 180-day 
gap definition of discontinuation, 33 (11.7%) patient was discontinued and discon-
tinuation period was 395.4±137.2 days (range: 189-1,023). Overall, 44.3% (n= 125) 
of patients were defined as Good Medication Possession Ratio (MPR) (≥ 90%) 
and 19.2% (n= 54) were as Poor MPR (< 70%). During follow-up period, 69 patients 
(24.5%) were deceased and the time to death for them was 3.18 years (1,159.5 ± 
845.1 days) after initiation of imatinib. Patients with Good MPR had significantly 
higher survival compared to patients with Poor MPR (p< 0.001). ConClusions: 
In a retrospective assessment of a large cohort of patients with CP-CML treated 
with imatinib, we have shown that nonadherence to therapy is important factor 
for survival. Adherence to therapy must be included as an important evaluation 
parameter in all future studies of CML
Limited information was available linking disease severity to QoL. ConClusions: 
In studies of patients receiving treatment for recurrent or metastatic SCCHN, 
median OS did not differ systematically among populations receiving regimens 
containing cetuximab, docetaxel, methotrexate, or paclitaxel. Among platinum-
refractory patients, no treatment was identified as having demonstrated signifi-
cant improvements in QoL.
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LiPegfiLgrAStim for reduCtioN of ChemotherAPy-iNduCed 
NeutroPeNiA reLAted eveNtS: A metA-ANALySiS
Bond TC1, Mueller U2, Barnes G3, Gennero R4, Tang B3, Schwartzberg L5
1Covance Market Access, Gaithersburg, MD, USA, 2Teva Pharmaceutical, Ulm, Germany, 3Teva 
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objeCtives: The purpose of the current meta-analysis was to compare the effi-
cacy of lipegfilgrastim (LIP) to pegfilgrastim (PEG) and filgrastim (FIL). Methods: 
EMBASE was searched for head-to-head trials examining the efficacy of LIP, PEG, or 
FIL. Outcomes included incidence of febrile neutropenia (FN), incidence of severe 
neutropenia (SN), duration of SN (DSN), and time to recovery of absolute neutrophil 
count (ANC). Direct comparisons of SN/FN between LIP and PEG were made using 
random-effects models estimating relative risk (RR). No trials directly compared 
LIP and FIL; indirect comparisons were made with PEG or placebo/no treatment 
(PLA) as the common comparator. For DSN/ANC recovery, generic inverse variance 
methods were employed. Results: Sixty-five studies were identified and 24 were 
included after full-text review and quality assessment via PRISMA criteria. Over all 
treatment cycles, LIP was non-inferior to PEG for risk of FN (RR 0.34, 95% CI: 0.05, 
2.14). The indirect estimate of FN for LIP versus FIL was also non-significant (RR 
0.22, 95% CI: 0.03, 1.51). For SN during cycle 1, LIP had a RR of 0.80 (95% CI: 0.63, 1.03) 
versus PEG and 0.79 (95% CI: 0.61, 1.03) versus FIL. For subsequent cycles, the RR 
was 0.53 (95% CI: 0.35, 0.79) LIP versus PEG and 0.45 (95% CI: 0.27, 0.75) versus FIL. 
Time to ANC recovery was significant: -1.75 days (95% CI: -2.61, -0.90) for LIP versus 
PEG and -1.88 days (95% CI: -2.82, -0.95) for LIP versus FIL. No comparions were 
significant for DSN. ConClusions: LIP showed non-inferiority to PEG for risk of 
at least one FN episode and SN in cycle 1. LIP was more effective than both PEG and 
FIL for prevention of SN in cycles 2-4 and reduced ANC recovery time. However for 
DSN differences were not significant. These results suggest that LIP is a possibly 
more effective treatment.
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ComPArAtive effeCtiveNeSS of grANuLoCyte CoLoNy-StimuLAtiNg 
fACtorS (g-CSf) for reduCiNg iNCideNCe of febriLe NeutroPeNiA (fN) 
–reLAted hoSPitALizAtioN: A retroSPeCtive Cohort Study uSiNg 
germAN CLAimS dAtA
Wetten S1, Li X2, Haas J3, Worth G4, Jacob C3, Braun S3, Tzivelekis S2
1Amgen Ltd, Uxbridge, UK, 2Amgen Inc, Thousand Oaks, CA, USA, 3Xcenda GmbH, Hannover, 
Germany, 4Amgen Ltd, Zug, Switzerland
objeCtives: Effectiveness of daily G-CSF prophylaxis can be decreased when 
given in short courses. The objective was to determine the difference in odds of 
FN-related hospitalizations with once per cycle G-CSF (pegfilgrastim) prophylaxis 
compared to daily G-CSF (filgrastim/lenograstim) prophylaxis for patients receiving 
high/intermediate FN-risk chemotherapy for breast cancer or Non-Hodgkin lym-
phoma (NHL). Methods: This retrospective cohort study used claims data from 
the Health Research Institute research database with < 4 million insured individuals 
in Germany. Patients receiving first-line, high/intermediate FN-risk chemotherapy 
for breast cancer or NHL from January 1, 2009 to December 31, 2013 were included 
and those cycles with G-CSF administration initiated ≤ 5 days following chemo-
therapy were assessed. G-CSF types were identified by ATC codes and FN-related 
hospitalizations within each cycle were identified by ICD-10-GM codes with a 
primary/secondary diagnosis of neutropenia (D70.1*, D70.7). Odds ratios (OR) for 
FN-related hospitalization and 95% confidence intervals (CI) were estimated with 
generalized estimating equation models and adjusted for age, gender, tumour type, 
metastatic status, cycle number, chemotherapy FN-risk and history of anaemia and 
surgery. Results: In total, 2,278 patients representing 7,918 cycles (6316 pegfil-
grastim, 1602 daily G-CSF) were included in the analysis; 2,037 (89%) patients had 
breast cancer and 241 (11%) had NHL. More than half of patients receiving pegfil-
grastim prophylaxis initiated it in cycle 1, primary prophylaxis, (56%) whereas 37% 
of patients receiving daily G-CSF prophylaxis initiated it in cycle 1. Three-quarters 
of patients receiving daily G-CSF were prescribed 5 or less doses in at least one 
cycle. Cycles with prophylactic daily G-CSF were associated with an increased 
risk of FN-related hospitalisations (adjusted OR= 2.19, 95% CI: 1.41-3.39; p-value 
< .001) in comparison to cycles with prophylactic pegfilgrastim. ConClusions: 
This comparative effectiveness analysis showed a significantly higher likelihood 
of FN-related hospitalizations in cycles with daily G-CSF prophylaxis versus those 
with pegfilgrastim prophylaxis.
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ANALySiS of eribuLiN meSyLAte doSiNg modifiCAtioNS imPACt oN 
AdmiNiStrAtioN PerSiSteNCe iN PAtieNtS with metAStAtiC breASt 
CANCer (mbC)
Feinberg BA1, Drenning J2, Garofalo DF1, Lal L3, Montgomery J2
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health, Dallas, TX, USA, 3Cardinal Health, Missouri 
City, TX, USA
objeCtives: Eribulin mesylate is a microtubule inhibitor FDA approved for 
patients with MBC after treatment with at least two prior chemotherapeutic regi-
mens. The recommended dose of eribulin is 1.4 mg/m2 administered on Days 1 
and 8 of a 21-day cycle with options for dose modification (dose reduction/dose 
delay) based on severity and duration of specific toxicities. Recent studies, limited 
to the clinical trial setting, have shown dose modifications lead to greater treat-
ment persistence and improved patient outcomes. This study utilized real-world 
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1.352) and 0.385(0.248; 0.596) respectively for OS and PFS. Survival extrapolation pro-
vided estimates of 8 month of additional OS gain for Lenvatinib vs. sorafenib, with 
MAIC extrapolation showing largest gain and a good model fit. ConClusions: This 
analysis demonstrated that in absence of head-to-head trials, MAIC is an important 
methodology to adjust for population and trial differences, especially in orphan dis-
eases where limited data are available. MAIC can increase reliability of comparative-
effectiveness data and support payers decision making.
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A deSCriPtioN of reAL-worLd treAtmeNt with AbirAteroNe ACetAte 
iN metAStAtiC CAStrAtioN-reSiStANt ProStAte CANCer PAtieNtS iN the 
PoSt-ChemotherAPy SettiNg iN frANCe ANd the NetherLANdS
Dearden L1, Musingarimi P2, Shalet N3, Demuth D4, Garcia Alvarez L4, Muthutantri A4, 
Venerus A4, Lasry R4, Hankins M4, Maher T3
1Janssen EMEA HEMAR, High Wycombe, UK, 2Janssen-Cilag Ltd., High Wycombe, UK, 3Janssen, 
High Wycombe, UK, 4IMS Health, London, UK
objeCtives: In the COU-AA-301 trial, abiraterone acetate with low-dose prednisone 
(AA) was found to extend survival in metastatic castrate resistant prostate cancer 
(mCRPC) patients progressing after docetaxel chemotherapy compared to placebo 
with low-dose prednisone. This study aimed to evaluate AA treatment duration in 
routine clinical practice in mCRPC patients in four European countries. Treatment 
sequencing and survival data were assessed to place the treatment duration into 
context. Results for France and the Netherlands are reported. Methods: The study 
was designed as a retrospective chart review. Patients were identified through treat-
ing oncologists and urologists. Eligible mCRPC patients were aged ≥ 18 years, pre-
viously treated with docetaxel and naïve to prior AA treatment. Baseline patient 
characteristics were described using summary statistics. Kaplan-Meier survival 
analyses were performed for AA treatment duration, overall survival (OS) and time 
to prostate-specific antigen (PSA) progression endpoints. Results: A total of 68 
physicians (France and the Netherlands) reported data on 269 mCRPC patients 
treated with AA. Median PSA (ng/mL) of patients from France and the Netherlands at 
baseline were 56.0 (interquartile range [IQR]: 28.0-120.0) and 174.5 (IQR: 69.5-371.5), 
respectively. The median time (months) between mCRPC diagnosis and AA initiation 
was 12.6 (IQR: 7.0-27.2) in France and 18.3 (IQR: 9.6-30.2) in the Netherlands. Median 
(months) AA treatment duration, median OS and median time to PSA progression in 
France was 11.3 (95% confidence interval [95%CI]: 8.3-13.7), 21.6 (95%CI: 14.5-.) and 
13.8 (95%CI: 11.0-14.7), respectively. In the Netherlands, it was 4.9 (95%CI: 3.4-6.4), 
11.0 (95%CI: 7.3-13.0) and 4.9 (95%CI: 3.0-7.3), respectively. ConClusions: Here we 
describe the real-world treatment of mCRPC patients receiving AA in the post-chem-
otherapy setting in two EU countries. This study suggests that initiating AA earlier 
in the post chemotherapy mCRPC setting may result in better health outcomes.
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reAL-worLd ANALySiS of tyroSiN KiNASe iNhibitor treAtemNt 
PAtterNS AmoNg PAtieNtS with ChroNiC myeLoid LeuKemiA iN KoreA
Shin S, Lee J, Kim J, Shin M, Park J, Kwon H
National Evidence based Health-care Collaborating Agency, Seoul, South Korea
objeCtives: To compare adherence, persistence and switching pattern of tyrosin 
kinase inhibitor (TKIs) imatinib, dasatinib, and nilotinib in patients with newly 
diagnosed Ph+ CML from Korean national health insurance (NHI) claims data-
base. Methods: Adults newly diagnosed Ph+ CML (ICD-10: C92.1) patients with 
imatinib, dasatinib, or nilotininb prescription claims between January 1, 2012 and 
December 31, 2012 were identified form the NHI claims database. The first day of TKI 
treatment following Ph+ CML diagnosis was defined as the index date. Adherence 
was measured using Medication possession ratio (MPR) (Poor MPR: < 70%, Good 
MPR ≥ 90%). Duration of TKI use was determined based on a gap in TKI of ≥ 180 
consecutive days after TKI initiation or switch to another TKI within the 180-day 
window. Results: A total of 304 patients were identified. The 184imatinib patients, 
the 70 dasatinib patients, and 51 nilotinib patients were similar in mean age, gender 
and comorbidity at baseline. Based on the 180-day gap definition of discontinua-
tion, it was not significantly different. Mean MPR (imatinib 89.1%, dasatinib 91.2%, 
nilotinib 91.6%, p-value= 0.4763) and persistency (imatinib 78.7%, dasatinib 88.5%, 
nilotinib 95.3%, p-value= 0.411) was also not significantly different among three 
groups. However, switch to second TKI therapy from index TKI in imatinib group was 
significantly higher than dasatinib and nilotinib (p< 0.001). Patients with Good MPR 
showed higher survival rate (p= 0.0039) and patients who do not switch to other TKIs 
showed higher survival rate (p= 0.0040). ConClusions: In a retrospective assess-
ment of patients with CP-CML treated with imatinib, dasatinib and nilotinib, using 
NHI claims data have shown that imatinib was used more frequently than other 
TKI in the first-line setting. Furthermore adherence and discontinuation was not 
different among patients receiving TKI. It would be needed to follow up how treat-
ment decisions for patients with CML are changed over time in routine clinical 
practice in Korea
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New drugS iN AdvANCed meLANomA: diSPAritieS iN requiremeNtS for 
PoSt-LAuNCh reAL-word evideNCe iN euroPe
Langham J, Floyd D
PHMR Ltd, London, UK
objeCtives: To determine country-specific requirements for real-world evidence 
(RWE) in Europe to support ongoing market access for new drugs to treat advanced 
melanoma. General perception suggests that RWE is crucial for demonstrating 
long-term value of innovative products. However, it is unclear how these percep-
tions correlate with absolute requirements of reimbursement agencies. Methods: 
We reviewed published health technology assessments (HTAs) and reimburse-
ment agency web sites for feasible data sources for melanoma RWE generation 
and guidance on collecting RWE in Europe. We also performed a pragmatic review 
of peer-reviewed literature to identify examples of published RWE in melanoma, 
and sought views of market access specialists from a global pharmaceutical com-
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eroLtiNib PLuS gemCitAbiNe ComPAred with gemCitAbiNe 
moNotherAPy iN PAtieNtS with PANCreAtiC CANCer: A reAL-worLd 
ANALySiS of KoreAN NAtioNA-wide dAtAbASe
Shin S1, Park C2, Kwon H1, Suh J1, Cho S1, Shin M1
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objeCtives: This national population-based retrospective study aimed to evaluate 
the relative effectiveness of adding erlotinib to gemcitabine with pancreatic cancer 
patients compared to gemcitabine in real clinical practice. Methods: Patients was 
identified retrospectively using Korean National Health Insurance claims database 
who pancreatic cancer (ICD-10: C25) who initiated chemotherapy with gemcitabine 
or erlotinib between January 1, 2007 and December 31, 2012. To be included in the 
study population, patients were required to have a history of intervention for histo-
logic or cytologic diagnosis within one year before chemotherapy. For homogeneity, 
patients were excluded if they have diagnosed with other cancers where gemcit-
abine is indicated or prior radiotherapy or surgical treatment. Results: A total 
of 4,267 patients were included. Overall survival was not significantly longer in 
patients treated with gemcitabine/erlotinib (median 6.77 months for gemcitabine/
erlotinib vs. 6.68 months for gemcitabine, p= 0.0977). One-year survival rate was 
also not significantly different (27.0% vs. 27.3%; p= 0.5988). Based on this relative 
effectiveness, incremental cost per life year gained over gemcitabine was estimated 
at USD 70,843.64 for gemcitabine plus erlotinib. ConClusions: Combination of 
gemcitabine/erlotinib of advanced pancreatic cancer is not more effective than 
gemcitabine monotherapy in a real-world setting. It does not provide reasonable 
cost-effectiveness over gemcitabine alone, and reimbursement strategies for pan-
creatic cancer in Korea could be reconsidered.
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the reLAtive effiCACy ANd SAfety of treAtmeNtS iN SeCoNd-LiNe 
mANAgemeNt of ChroNiC myeLoid LeuKAemiA: SyStemAtiC review ANd 
NetworK metA-ANALySiS feASibiLity Study
Kroes MA1, Witkowski MA1, Paine A2, Zagorska A3, Almeida AM4
1Abacus International, Bicester, UK, 2Zedediah Consulting, Wokingham, UK, 3Bristol-Myers 
Squibb, Rueil Malmaison, France, 4Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
objeCtives: To assess relative efficacy and safety of second-line treatments in 
chronic myeloid leukaemia (CML), a systematic review (SR) and network meta-
analysis (NMA) feasibility study were conducted. Methods: A SR was conducted 
in January 2015 (Embase, MEDLINE, Cochrane Library, Clintrials.gov and conferences) 
to identify comparative trials evaluating treatment outcomes in patients with CML 
previously treated with tyrosine kinase inhibitors. Eligible studies were examined 
to assess NMA feasibility. Results: Twenty-three publications relating to six ran-
domised controlled trials (RCTs) on second-line treatment met the eligibility criteria. 
Included studies compared either nilotinib (n= 3) or dasatinib (n= 1) with imatinib, or 
studied dasatinib at alternative doses (n= 2). No comparative bosutinib or ponatinib 
studies were identified. Efficacy outcomes were reported using various definitions 
and different time points. Compared with nilotinib, significantly fewer imatinib 
treated patients with complete cytogenetic response (CCyR) at baseline, achieved 
complete molecular response (CMR) (23% vs 11%, p= 0.02) by 12 and confirmed CMR 
(22.1% vs 8.7%, p= 0.0087) by 24 months and in patients without major molecular 
response (MMR) at baseline, MMR by 12 (75% vs 36%, p= 0.006) and 24 (83.3% vs 
53.6%, p= 0.0342) months. Compared with imatinib, significantly more dasatinib 
patients achieved CCyR (16% vs 40%, p= 0.004; 18% vs 44%, p= 0.0025), MMR (4% vs 
16%, p= 0.038; 12% vs 29%, p= 0.028) and complete haematologic response (82% vs 
93%, p= 0.034; 82% vs 93%, p= 0.0341) at 15 and 24 months, respectively. Interpretation 
of safety data was inconclusive due to its limited availability and treatment expo-
sure differences. Even considering prospective non-RCTs, NMA was not feasible 
due to missing network links, significant differences between trial populations, 
and varying follow-up times. ConClusions: Review of all published comparative 
studies on second-line treatment of CML confirms that, based on direct efficacy 
results, dasatinib and nilotinib are the second line agents of choice. NMA comparing 
nilotinib and dasatinib was not feasible.
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mAtChiNg-AdjuSted iNdireCt treAtmeNt ComPAriSoN ANd SurvivAL 
extrAPoLAtioN iN rAdioiodiNe-refrACtory differeNtiAted thyroid 
CANCer (rAi-refrACtory dtC): uPdAted ANALySiS
Tremblay G1, Pelletier C1, Forsythe A2, Majethia U2
1Eisai, Woodcliff Lake, NJ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA
objeCtives: Indirect treatment comparisons (ITCs) are important when evaluat-
ing comparative-effectiveness in absence of head-to-head clinical trials. Classic 
ITCs can lead to biased results due to differences in patient populations and trial 
designs. These differences can be corrected for by using matching-adjusted-ITC 
(MAIC) technique. Furthermore, extrapolation of survival data beyond clinical trial 
results may be required for economic evaluations. The objective of this research 
was to compare lenvatinib and sorafenib in patients with RAI-Refractory DTC using 
MAIC and survival extrapolation techniques. This analysis is an update to the MAIC 
published previously using a later data cut-off date for both drugs. Methods: Mean 
overall-survival (OS) and progression-free survival (PFS) outcomes were estimated 
by weighting patient-level data based on baseline characteristics from individual 
phase III trials using logistic regression. Classic ITC was performed before and 
after adjustment. Cross-over correction was also applied. Extrapolation of OS and 
PFS was performed using proportional hazard, accelerated time failure, individual 
parametric models and piecewise models. Results were presented as hazard-ratios 
(HR) with confidence-intervals (CI). Results: Unadjusted ITCs for Lenvatinib vs. 
placebo were 0.545(0.350; 0.830) for OS and 0.213(0.158; 0.288) for PFS. MAIC pro-
vided statistically significant estimates of 0.505(0.300; 0.820) for OS and 0.227(0.159; 
0.326) for PFS vs. placebo. Unadjusted ITCs vs. sorafenib were 0.790(0.453; 1.379) and 
0.361(0.244; 0.534) respectively for OS and PFS; while MAIC results were 0.732(0.396; 
